Table 2. Disease characteristics at the time of oligoprogression.
| Variable | N (%) |
|---|---|
| Type of immunotherapy (CPI Strategy) | |
| Monotherapy | 4 (16.7) |
| Combination | 20 (83.3) |
| Lines of immunotherapy before oligoprogression | |
| 1 | 16 (66.7) |
| 2 | 5 (20.8) |
| 3 | 3 (12.5) |
| Response to immunotherapy before oligoprogression | |
| CR | 6 (25.0) |
| PR | 18 (75.0) |
| No. of oligoprogression | |
| 1 | 14 (58.3) |
| 2 | 10 (41.7) |
| Site of oligoprogression | |
| Brain | 14 (41.2) |
| Lung | 10 (29.4) |
| Lymph node | 5 (14.8) |
| Adrenal gland | 3 (8.8) |
| Liver | 1 (2.9) |
| Cervical vertebra | 1 (2.9) |
| Pattern of oligoprogression | |
| New metastasis | 16 (47.1) |
| Existing metastasis | 18 (52.9) |
| Type of immunotherapy after oligoprogression (CPI Strategy-PO) | |
| Monotherapy | 7 (29.2) |
| Combination | 17 (70.8) |
| Change of CPI Strategy | |
| Consistent Strategy (continue previous treatment or maintenance strategy) | 17 (70.8) |
| Monotherapy to combination | 3 (8.8) |
| Adjusted combination | 4 (16.7) |
Values presented are n (%) unless otherwise noted. CPI, checkpoint inhibitor; CR, complete response; PR, partial response; CPI Strategy-PO, strategy of checkpoint inhibitor post oligoprogression.